Neogen Chemicals Limited has informed the Exchange about Transcript
NEOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neogen Chemicals delivered strong Q4 FY26 with consolidated revenue of INR 247 crore (+22% YoY) and EBITDA of INR 44 crore (+21% YoY) at 17.8% margin. FY26 full-year revenue stood at INR 862 crore (+11% YoY) with PAT of INR 29 crore. The company has revised battery materials project costs upward — Pakhajan Phase 2 now INR 1,367 crore (March 2027) and Dahej Phase 1 INR 428 crore (Feb 2027) — citing design optimization and higher localization of subcomponents. Promoter infused INR 161 crore via preferential allotment; INR 60 crore insurance tranche received in February bringing cumulative receipts to INR 140 crore plus INR 7 crore salvage. Management guides FY27 standalone revenue of INR 875-950 crore (non-battery) and battery chemicals revenue of INR 300 crore+ (weighted to H2). ROCE target remains 18-20% even after revised capex. Consolidated net debt stands at INR 1,295 crore.
Strong quarterly performance with volume-driven growth across organic and inorganic chemicals. Battery chemicals business is on track with customer approvals from US-based electrolyte makers. Higher project costs and elevated debt levels are offset by insurance recoveries and Morita JV equity infusion expected H1FY27, reducing near-term funding risk.